Trial
NCT00275314
WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pittsburgh
Collaborators
Hoffmann-La Roche
Condition
Kidney Transplant
Intervention
Valganciclovir
Why stopped
Study never started at our site Funding issue
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-17